SA14-14-2 vaccine
Showing 1 - 25 of >10,000
Encephalitis, Japanese Trial (Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine)
Completed
- Encephalitis, Japanese
- Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
- (no location specified)
Sep 24, 2020
Encephalitis, Japanese, Measles, Mumps Trial in Manila (Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles,
Completed
- Encephalitis, Japanese
- +3 more
- Live attenuated SA 14-14-2 Japanese Encephalitis vaccine
- Measles, mumps, rubella vaccine
-
Manila, PhilippinesResearch Institute for Tropical Medicine
Sep 18, 2020
Japanese Encephalitis Trial in Homagama, Kolonnawa, Moratuwa (Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV))
Completed
- Japanese Encephalitis
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
-
Homagama, District Of Colombo, Sri Lanka
- +2 more
Mar 18, 2020
Encephalitis, Japanese B Trial in Manila (Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV))
Completed
- Encephalitis, Japanese B
- Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)
- Measles Vaccine (MV)
-
Manila, PhilippinesResearch Institute for Tropical Medicine
Feb 25, 2020
COVID-19 Trial in Chengdu (LYB002V14, LYB002V14A, LYB002CA)
Active, not recruiting
- COVID-19
- LYB002V14
- +2 more
-
Chengdu, Sichuan, ChinaAffiliated Hospital of North Sichuan MedicalCollege
Jun 29, 2023
Influenza, Human Trial (sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3)
Not yet recruiting
- Influenza, Human
- sa-mRNA vaccine Dose 1
- +4 more
- (no location specified)
Sep 7, 2023
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women
Not yet recruiting
- HPV Infection
- +2 more
- Follow up
-
Fuzhou, Fujian, ChinaFujian Maternity and Child Health Hospital
Nov 16, 2023
Schistosomiasis Mansoni, Schistosomiasis Haematobium, Vaccination; Infection Trial in Saint Louis (Sm14 recombinant vaccine+
Recruiting
- Schistosomiasis Mansoni
- +2 more
- Sm14 recombinant vaccine+ GLA-SE adjuvant
-
Saint Louis, SenegalBiomedical Research Center EPLS
Dec 13, 2022
COVID-19 Trial in Nanjing (Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14,
Recruiting
- COVID-19
- Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
- +7 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022
Smallpox, Monkeypox, Cowpox Trial in Novosibirsk (NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally,
Completed
- Smallpox
- +3 more
- NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
- +5 more
-
Novosibirsk, Koltsovo, Novosibirsk Region, Russian FederationFederal State Budgetary Healthcare Institution - Medical and San
Jul 27, 2023
Pain Trial in Seville (Painless Vaccination)
Completed
- Pain
- Painless Vaccination
-
Seville, Andalucia, SpainDistrito Sanitario Aljarafe-Sevilla Norte
Aug 16, 2023
Papillomavirus Infections Trial in Quzhou, Taizhou (9vHPV vaccine)
Active, not recruiting
- Papillomavirus Infections
- 9vHPV vaccine
-
Quzhou, Zhejiang, China
- +1 more
Sep 1, 2022
Healthy Trial (BI 1810631 (C-14) formulation 1, BI 1810631, BI 1810631 (C-14) formulation 2)
Not yet recruiting
- Healthy
- BI 1810631 (C-14) formulation 1
- +2 more
- (no location specified)
May 25, 2023
Dengue, Dengue Fever, Dengue Hemorrhagic Fever Trial in Worldwide (Live, attenuated, dengue serotype 1, 2, 3, 4 virus, Placebo:
Completed
- Dengue
- +2 more
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Placebo: Sodium chloride (NaCl) 0.9%
-
Denpasar, Bali, Indonesia
- +11 more
Mar 10, 2022
NSCLC Trial in Guangzhou (PLB1001)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Aug 15, 2023
Healthy Trial in Groningen (BI 764198 (C-14) (approach 1), BI 764198 (C-14) (approach 2))
Recruiting
- Healthy
- BI 764198 (C-14) (approach 1)
- BI 764198 (C-14) (approach 2)
-
Groningen, NetherlandsICON
May 8, 2023
Healthy Volunteers Trial in Leeds (E7386 Tablet, (14C)E7386 Capsule, (14C)E7386)
Recruiting
- Healthy Volunteers
- E7386 Tablet
- +2 more
-
Leeds, United KingdomLabcorp Clinical Research Unit
Oct 31, 2022
HPV InfectioN, HPV-Related Carcinoma Trial in China (Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell), )
Active, not recruiting
- HPV InfectioN
- HPV-Related Carcinoma
- Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell)
- placebo
-
Nanning, Guangxi, China
- +4 more
Sep 10, 2023
Diphtheria, Tetanus, Pertussis Trial (LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin
Not yet recruiting
- Diphtheria
- +5 more
- LBVD (Hexavalent vaccine)
- Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)
- (no location specified)
Jul 13, 2022
VIDAS® NEPHROCLEAR Diagnostic Accuracy Study
Active, not recruiting
- Acute Kidney Injury
- +2 more
- VIDAS® NEPHROCLEAR™ CCL14 Test
-
Washington, District of Columbia
- +1 more
Sep 7, 2023
Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)
Not yet recruiting
- Gastrointestinal Stromal Tumors
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2023
Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease Trial in Mexico City (CYD Dengue Vaccine, Human
Completed
- Dengue Fever
- +2 more
- CYD Dengue Vaccine
- Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
-
Mexico City, Mexico(unnamed)
Mar 15, 2022
Healthy Trial in Austin ([phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471)
Recruiting
- Healthy
-
Austin, TexasPPD Phase I Clinic
Jun 29, 2023
Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax Trial (Venetoclax, Dexamethasone Oral)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- +2 more
- Venetoclax
- Dexamethasone Oral
- (no location specified)
Aug 16, 2023
Healthy Participants Trial in Groningen (Oral [14C]PF-07081532, Oral PF-07081532 and IV [14C]PF-07081532)
Recruiting
- Healthy Participants
- Oral [14C]PF-07081532
- Oral PF-07081532 and IV [14C]PF-07081532
-
Groningen, NetherlandsPRA Health Sciences
Jan 5, 2023